- Home
- HHS vs KZR Comparison
HHS vs KZR Comparison
Compare HHS & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- KZR
- Stock Information
- Founded
- HHS 1923
- KZR 2015
- Country
- HHS United States
- KZR United States
- Employees
- HHS N/A
- KZR N/A
- Industry
- HHS Advertising
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- KZR Health Care
- Exchange
- HHS Nasdaq
- KZR Nasdaq
- Market Cap
- HHS 26.9M
- KZR 29.7M
- IPO Year
- HHS N/A
- KZR 2018
- Fundamental
- Price
- HHS $3.34
- KZR $6.15
- Analyst Decision
- HHS
- KZR Hold
- Analyst Count
- HHS 0
- KZR 4
- Target Price
- HHS N/A
- KZR $6.00
- AVG Volume (30 Days)
- HHS 290.4K
- KZR 465.5K
- Earning Date
- HHS 11-13-2025
- KZR 11-07-2025
- Dividend Yield
- HHS N/A
- KZR N/A
- EPS Growth
- HHS N/A
- KZR N/A
- EPS
- HHS N/A
- KZR N/A
- Revenue
- HHS $174,951,000.00
- KZR N/A
- Revenue This Year
- HHS $6.54
- KZR N/A
- Revenue Next Year
- HHS N/A
- KZR N/A
- P/E Ratio
- HHS N/A
- KZR N/A
- Revenue Growth
- HHS N/A
- KZR N/A
- 52 Week Low
- HHS $3.06
- KZR $3.53
- 52 Week High
- HHS $7.45
- KZR $8.45
- Technical
- Relative Strength Index (RSI)
- HHS 42.94
- KZR 75.21
- Support Level
- HHS $3.26
- KZR $6.06
- Resistance Level
- HHS $3.65
- KZR $6.30
- Average True Range (ATR)
- HHS 0.18
- KZR 0.25
- MACD
- HHS -0.02
- KZR 0.11
- Stochastic Oscillator
- HHS 10.09
- KZR 89.13
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.